Quest Diagnostics Incorporated (NYSE:DGX) saw its share price trade relatively negative in the recent trading session. The share price was last updated to $76.7 with a loss of -0.75 points or -0.97%. The net money flow was $0.87 million and the up/down ratio was 1.2. Approximately $5.25 million was the inflow in upticks and $4.38 million was the outflow in downticks. On a weekly measure, the shares have seen a price change of -0.74%.The shares witnessed a block transaction with a net money flow of $1.79 million. The total money in uptick was $2.85 million and in downtick was $1.06 million with the up/down ratio reaching 2.69.
Currently the company Insiders own 1.5% of Quest Diagnostics Incorporated shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -7.12% . Institutional Investors own 93.51% of Quest Diagnostics Incorporated shares. During last six month period, the net percent change held by insiders has seen a change of -7.27%. On the companys insider trading activities, The Securities and Exchange Commission has divulged that Doherty Catherine T., officer (SVP, Clin. Franchise Solutions) of Quest Diagnostics Inc, had unloaded 47,334 shares at an average price of $77.27 in a transaction dated on May 27, 2016. The total value of the transaction was worth $3,657,498.
Quest Diagnostics Incorporated (NYSE:DGX) stock ended Monday session in the red zone in a volatile trading. The stock closed down 0.97 points or 1.25% at $76.48 with 1,420,073 shares getting traded. Post opening the session at $77.2, the shares hit an intraday low of $76.1901 and an intraday high of $77.43 and the price was in this range throughout the day. The company has a market cap of $10,819 million and the number of outstanding shares have been calculated to be 141,457,180 shares. The 52-week high of Quest Diagnostics Incorporated (NYSE:DGX) is $78.97 and the 52-week low is $59.655.
Many analysts have stated their opinion on the company shares. Credit Suisse initiates coverage on Quest Diagnostics Incorporated (NYSE:DGX). In the latest research report, Credit Suisse announces the target price to $72 per share. According to the latest information available, the shares are now rated Neutral by the analysts at the agency. The rating by the firm was issued on March 15, 2016.
Quest Diagnostics Incorporated is a provider of diagnostic testing information services. The Company consists of two businesses: Diagnostic Information Services and Diagnostic Solutions. Diagnostic Information Services business, consists of two parts, develops and delivers diagnostic testing, information and services to patients, physicians, health plans, hospitals, accountable care organizations (ACOs), integrated delivery networks (IDNs), other commercial laboratories, patients and other customers. Diagnostics Information Services business also provides diagnostic information services, which includes providing clinical testing services, such as routine testing, gene-based and esoteric testing, anatomic pathology services and drugs-of-abuse testing. Diagnostic Solutions includes the Companys other businesses, including central laboratory testing for pharmaceutical and medical device clinical trials, risk assessment services, diagnostic products and healthcare information technology.